Associations between KRAS or BRAF mutation and worse outcomes were reported in North Central Cancer Treatment Group N0147 trial, in which prognostic impact of KRAS and BRAF mutants were involved with stage III colon cancer patients received FOLFOX with or without cetuximab32. The gene discussed is KRAS; the disease is colonic neoplasm.